Efficacy & Safety

Once-daily dosing means nebulized maintenance
therapy can conveniently fit into your patients'
day1

Not an actual patient.

24-HOUR
EFFICACY

Improved lung function over 12 weeks for better breathing and symptom relief.1

View Efficacy Data

YUPELRI was studied in two 12-week, randomized, double-blind, placebo-controlled, parallel-group confirmatory studies (Studies 1 and 2) to evaluate the efficacy of YUPELRI vs placebo in patients with moderate to very severe COPD.

YUPELRI is the first and only once-daily nebulized maintenance LAMA for patients experiencing ongoing symptoms on their current treatment regimen.1,2

Demonstrated Safety Profile

See how YUPELRI was shown to be well
tolerated in clinical trials.1

View Safety Data

Novel Chemical Structure

Learn about the distinct chemical structure of
YUPELRI and defined pharmacologic effects.

See Mechanism of Action

The primary endpoint was change from baseline in trough (predose) FEV1 at day 85 vs placebo: YUPELRI demonstrated a statistically significant difference vs placebo in Study 1 (146 mL, P<0.0001 [YUPELRI, N=189; placebo, N=191]) and Study 2 (147 mL, P<0.0001 [YUPELRI, N=181; placebo, N=187]).1,24

In addition, a prespecified exploratory analysis was performed using serial spirometry on a substudy population over 24 hours on days 84/85. In Study 1, LS mean changes from baseline in FEV1 ranged from 55.8 mL to 240.4 mL in the YUPELRI group (N=45), and from -113.6 mL to 59.6 mL in the placebo group (N=44). In Study 2, LS mean changes from baseline in FEV1 ranged from 19.8 mL to 148.5 mL in the YUPELRI group (N=44), and from -176.4 mL to -13.0 mL in the placebo group (N=39).1,24

CI=confidence interval; COPD=chronic obstructive pulmonary disease; FEV1=forced expiratory volume; LAMA=long-acting muscarinic antagonist; LS=least squares.